Bone Morphogenetic Protein-2 (BMP-2) Activates NFATc1 Transcription Factor via an Autoregulatory Loop Involving Smad/Akt/Ca\textsuperscript{2+} Signaling*

Received for publication, June 2, 2015, and in revised form, September 23, 2015. Published, JBC Papers in Press, October 15, 2015, DOI 10.1074/jbc.M115.668939

Chandi C. Mandal\textsuperscript{1,1}, Falguni Das\textsuperscript{5}, Suthakar Ganapathy\textsuperscript{4}, Stephen E. Harris\textsuperscript{4}, Goutam Ghosh-Choudhury\textsuperscript{5,11,12,21}, and Nandini Ghosh-Choudhury\textsuperscript{11,12,21}

From\textsuperscript{11} Veterans Affairs Research and \textsuperscript{21}Geriatric Research Education and Clinical Center, South Texas Veterans Health Care System and Departments of \textsuperscript{11}Pathology, \textsuperscript{5}Medicine, and \textsuperscript{21}Periodontics, University of Texas Health Science Center, San Antonio, Texas 78229

Background: Mutations in NFATc1 and BMP-2 genes result in bone abnormalities in mice.

Results: BMP-2 activates intracellular Ca\textsuperscript{2+} release, thus activating calcineurin phosphatase to induce NFATc1 expression involving canonical Smad and noncanonical PI 3-kinase in osteoblasts.

Conclusion: BMP-2-stimulated Ca\textsuperscript{2+}-calcineurin-NFATc1 axis potentiates osteoblast differentiation.

Significance: NFATc1 autoregulates its expression in response to BMP-2 in osteoblasts.

Bone remodeling is controlled by dual actions of osteoclasts (OCs) and osteoblasts (OBs). The calcium-sensitive nuclear factor of activated T cells (NFAT) c1 transcription factor, as an OC signature gene, regulates differentiation of OCs downstream of bone morphogenetic protein-2 (BMP-2)-stimulated osteoblast-coded factors. To analyze a functional link between BMP-2 and NFATc1, we analyzed bones from OB-specific BMP-2 knock-out mice for NFATc1 expression by immunohistochemical staining and found significant reduction in NFATc1 expression. This indicated a requirement of BMP-2 for NFATc1 expression in OBs. We showed that BMP-2, via the receptor-specific Smad pathway, regulates expression of NFATc1 in OBs. Phosphatidylinositol 3-kinase/Akt signaling acting downstream of BMP-2 also drives NFATc1 expression and transcriptional activation. Under the basal condition, NFATc1 is phosphorlated. Activation of NFAT requires dephosphorylation by the calcium-dependent serine/threonine phosphatase calcineurin. We examined the role of calcium in BMP-2-stimulated regulation of NFATc1 in osteoblasts. 1,2Bis(2aminophenoxy)ethaneN,N',N'',N''-tetraacetic acid acetoxymethyl ester, an inhibitor of intracellular calcium abundance, blocked BMP-2-induced transcription of NFATc1. Interestingly, BMP-2 induced calcium release from intracellular stores and increased calcineurin phosphatase activity, resulting in NFATc1 nuclear translocation. Cyclosporin A, which inhibits calcineurin upstream of NFATc1, blocked BMP-2-induced NFATc1 mRNA and protein expression. Expression of NFATc1 directly increased its transcription and VIVIT peptide, an inhibitor of NFATc1, suppressed BMP-2-stimulated NFATc1 transcription, confirming its autoregulation. Together, these data show a role of NFATc1 downstream of BMP-2 in mouse bone development and provide novel evidence for the presence of a cross-talk among Smad, phosphatidylinositol 3-kinase/Akt, and Ca\textsuperscript{2+} signaling for BMP-2-induced NFATc1 expression through an autoregulatory loop.

The skeleton provides structural stability for daily activities, and it uniquely responds to mechanical loading and unloading. The mechanical stress signals are translated into physiological responses for sustaining optimum bone quality. Maintenance of skeletal balance relies on bone remodeling coordinated by actions of bone-forming osteoblasts, the mechanical and biological signal-sensing osteocytes, and the bone-resorbing osteoclasts (1). Bone is the major calcium storage organ in the body. Calcium signaling is necessary for differentiation and activity of osteoblasts and osteoclasts (2–4). Osteoclast differentiation is dependent on stromal cell/osteoblast-derived factors, colony-stimulating factor 1 (CSF-1), and receptor activator of NF\kappa B ligand (RANKL)\textsuperscript{4} (5). High calcium concentration induces osteoclast formation by increasing RANKL expression (6).

The nuclear factor of activated T cells (NFAT) is involved in calcium-induced RANKL expression in osteoblasts (7). NFATs represent a family of transcription factors that were originally discovered as inducible nuclear factors associated with inter-

* This work was supported in part by Veterans Affairs Merit Review grants and National Institutes of Health Grant R01 AR52425 (G. G.-C.) and National Institutes of Health Grant R01 DK50190 and Veterans Affairs Merit Review grants (to G. G.-C.). The authors do not have any conflict of interests. The abbreviations used are: RANKL, receptor activator of NF\kappa B ligand; BMP, bone morphogenetic protein; CsA, cyclosporin A; Ad, adenoviral vector; DN, dominant negative; Luc, luciferase reporter; SBE, Smad binding element; NFAT(c), nuclear factor of activated T cells (cytoplasmic); PI, phosphatidylinositol; BAPTA-AM, 1,2bis(2aminophenoxy)ethaneN,N',N''-tetraacetic acid acetoxymethyl ester; CSF-1, colony-stimulating factor 1; BMPR, BMP receptor; FRC, fetal rat calvarial bone; qRT-PCR, quantitative RT-PCR; BMP-2 cKO, osteoblast-specific BMP-2-null; Ly, Ly294002; PTEN, phosphatase and tensin homolog.

** The abbreviations used are: RANKL, receptor activator of NF\kappa B ligand; BMP, bone morphogenetic protein; CsA, cyclosporin A; Ad, adenoviral vector; DN, dominant negative; Luc, luciferase reporter; SBE, Smad binding element; NFAT(c), nuclear factor of activated T cells (cytoplasmic); PI, phosphatidylinositol; BAPTA-AM, 1,2bis(2aminophenoxy)ethaneN,N',N''-tetraacetic acid acetoxymethyl ester; CSF-1, colony-stimulating factor 1; BMPR, BMP receptor; FRC, fetal rat calvarial bone; qRT-PCR, quantitative RT-PCR; BMP-2 cKO, osteoblast-specific BMP-2-null; Ly, Ly294002; PTEN, phosphatase and tensin homolog.
leukin 2 (IL-2) promoter during T cell activation (8). NFATs regulate production of crucial growth factors, cytokines, and cellular proteins that coordinate cell growth and differentiation. There are five members in the NFAT family designated as NFATc1–4, regulated by the intracellular calcium-calmodulin-dependent phosphatase calcineurin and the calcium-independent NFAT5. In resting cells, inactive NFATc1–4 are highly phosphorylated and localized in the cytoplasm. An increase in intracellular calcium concentration activates the serine/threonine phosphatase calcineurin (9). Calcineurin removes critical phosphates from the N terminus of these NFAT proteins, thus exposing a nuclear transport sequence and facilitating their nuclear import (9). Once in the nucleus, NFATs form active transcriptional complexes by pairing with different coactivating proteins. One such partner is identified to be the osteoblastic transcription factor osterix (10). Of the five NFAT isoforms, expression in the mouse osteoblasts is limited to NFATc1 and NFATc3 where NFATc1 regulates NFATc3 expression (7). Calcineurin and NFATc1 control osteoblast proliferation and expression of tartrate-resistant acid phosphatase, the osteoclast-associated receptor cathepsin K, and calcitonin receptor to induce osteoclast differentiation (11–13). NFATc proteins play critical roles in regulating different developmental pathways including bone formation as evidenced by bone formation abnormalities in mice with mutations in NFATc1 and NFATc2 genes (10, 14).

Bone morphogenetic protein-2 (BMP-2) orchestrates osteoblast differentiation and controls osteoclast survival, maturation, and activation by regulating expression of RANKL and CSF-1 (15–20). BMPs signal through type I (BMPR I) and type II (BMPR II) transmembrane receptors. Binding of BMPs to BMPR II recruits BMPR I and activates it by phosphorylation in the GS domain (GS domain consisting of multiple glycine and serine residues) (21, 22). This initiates the intracellular signal transduction by BMPs as the activated BMPR I phosphorylates receptor-activated Smads 1, 5, and 8 that in turn bind to Smad4 and translocate to the nucleus to regulate gene transcription (23, 24). BMP-2 orchestrates integration of Smad signaling with non-Smad signaling in osteoblasts to control their differentiation and gene transcription. A critical role of BMP-2-activated phosphatidylinositol 3-kinase and its downstream partner Akt kinase is established in BMP-2-induced osteoblast differentiation and CSF-1 expression and secretion from osteoblasts to support active osteoclast formation (15, 25). NFATc1 regulates osteoclast differentiation by transcriptionally activating RANKL that feeds back to induce NFATc1 (7, 12, 26). Experimental evidence also suggests a role of NFATc1 in osteoblast-assisted osteoclast activity (13). Both BMP-2 and NFATc1 are essential for driving osteoblast differentiation and osteoblast-mediated osteoclast activity, but a link between these two master regulators of bone remodeling has yet to be described. Here we demonstrate that BMP-2 mobilizes intracellular Ca$^{2+}$ to activate calcineurin phosphatase, leading to NFATc1 transactivation in osteoblasts that in turn leads to autoregulation of NFATc1 gene expression mediated by BMP-2-assisted cross-talk of Smad and PI 3-kinase signaling.

**Experimental Procedures**

**Materials**—Recombinant BMP-2 was a gift from Wyeth Pharmaceutical (Cambridge, MA). Tissue culture media, serum, and the nuclear fraction extraction kit (NE-PER) were obtained from Life Technologies. Cell transfection reagent FuGENE HD and luciferase assay kits were purchased from Promega Inc. (Madison, WI). Anti-actin antibody and TRI reagent for RNA isolation were purchased from Sigma. NFATc1, GSK3β, Smad1/5, Smad6, and lamin B antibodies were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX). Phospho-GSK3β and phospho-Smad1/5 antibodies were from Cell Signaling Technology (Danvers, MA).

**Cells and Plasmids**—C2C12 cells were purchased from ATCC (Manassas, VA). Primary osteoblasts from fetal rat calvarial bone (FRC) were isolated using controlled digestion with trypsin and collagenase (25). C2C12 cells were maintained in DMEM, whereas FRC and murine 2T3 preosteoblast cells (29) were cultured in DMEM or α-minimal essential medium, respectively, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO₂ in air. The confluent cells were serum-starved for 24 h and then treated with varying doses of recombinant BMP-2 in serum-free medium for the indicated periods of time in the presence or absence of different agents. NFATc1 promoter-luciferase constructs were obtained from Dr. Edgar Serfling (University of Wuerzburg, Germany). VIVIT plasmid was purchased from Addgene (Cambridge, MA).

**RNA Extraction and Quantitative RT-PCR Analysis**—Total RNA was isolated from C2C12 and 2T3 cells in the presence or absence of BMP-2 for the indicated periods of time. If not otherwise described BMP-2 treatment was routinely carried out for 24–48 h. To investigate the signaling mechanism, cells were preincubated with different agents before addition of BMP-2. RNA extraction and quantitative RT-PCR (qRT-PCR) analysis were carried out as described earlier (30–32). In brief, RNA was extracted with TRI reagent. 1 μg of total RNA was reverse transcribed to make cDNA using an RT-PCR First Strand kit (Life Technologies). cDNA was next amplified and quantified in 96-well plates using an ABI Prism 7300 sequence detection system and analyzed by SDS 2.1 software using SYBR Green probe (Applied Biosystems, Foster City, CA). The PCR protocol was as follows: initial denaturation at 94 °C for 10 min followed by 40 cycles at 94 °C for 15 s, annealing at 58 °C for 30 s, and extension at 72 °C for 30 s. PCRs were performed in triplicate for each cDNA and averaged, and the relative mRNA levels were normalized to the reference mouse GAPDH gene (Qiagen, Valencia, CA). NFATc1 primers were used as described by Chuvpilo et al. (33).

**Transfection and Reporter Assay**—Transfection of respective plasmid DNA into cells in 24-well plates was performed with 60–70% confluent cells in serum-free medium as described previously using FuGENE HD according to the manufacturer’s protocol (25, 34, 35). Luciferase activity was quantified 24–48 h post-transfection using a luciferase assay kit. The data were plotted as mean luciferase activity/μg of protein as arbitrary units ± S.E.
\textbf{BMP-2 Regulates NFATc1 Expression}—Cell lysates were prepared using radioimmune precipitation assay buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na\textsubscript{3}VO\textsubscript{4}, 1 mM PMSF, 0.1% protease inhibitor mixture, and 1% Nonidet P-40), and protein concentration was determined using Bio-Rad protein assay reagent. Equal amounts of protein (20–40 \mu g) were resolved by SDS-gel electrophoresis with or without immunoprecipitation using specific antibodies and transferred to PVDF membrane as described earlier (25, 34, 35). The membranes were incubated for 1 h at room temperature in Tris-buffered saline and 0.1% Tween 20 (TBST) containing 5% (w/v) nonfat dry milk and then treated overnight with primary antibody against NFATc1 (1:200), \beta-actin (1:5000), tubulin (1:1000), or lamin B (1:1000) in TBST containing 5% bovine serum albumin at 4 °C. Incubation in primary antibody was followed by incubation in the respective secondary antibody labeled with horseradish peroxidase at a 1:20,000 dilution for 1 h at room temperature, and detection of immunoreactive bands was done by HRP-chemiluminescence reagents (Thermo Science). Membranes were reprobed with antibody against \beta-actin, \beta- tubulin, or lamin B, which served as loading controls for whole cell lysates, cytoplasmic extracts, or nuclear extracts, respectively.

\textbf{Electrophoretic Mobility Shift Assay}—Nuclear extracts were prepared using the NE-PER kit. The oligonucleotide probe spanning either the Smad binding element (SBE) or a probe spanning either the Smad binding element (SBE) or the NFATc1 (NFATc1) probe were prepared using radioimmune precipitation assay buffer (20–40 \mu M) in the presence and absence of the phosphopeptide activity was measured using a colorimetric calcineurin cellular activity assay kit (Calbiochem/EMD Millipore) according to the manufacturer’s recommended protocol. Cell lysates were cleared by high speed centrifugation, and the supernatant was desalted by gel filtration. Phosphatase activity was determined in the purified lysates using RII phosphopeptide substrate. The activity was calculated as the difference in absorbance at 620 nm in the presence and absence of the phosphopeptide substrate.

\textbf{Measurement of Intracellular Calcium}—Changes of [Ca\textsuperscript{2+}] in osteoblast cells were determined in cell suspensions using the Ca\textsuperscript{2+}-sensitive fluorescent indicator Fura-2/AM (Molecular Probes) (37). Osteoblast cells grown to 80–90% confluence were harvested by trypsin-EDTA and loaded with 2 \mu M Fura-2/AM in PBS containing 0.01% BSA by incubating in the dark at 37 °C with gentle agitation for 20 min. 2-ml aliquots of the Fura-2-loaded cells (1.5 \times 10\textsuperscript{6} cells/ml) were washed, resuspended in fresh medium, and placed in 4-ml cuvettes. [Ca\textsuperscript{2+}] release was measured using a Deltascan fluorometer (Photon Technology International, Edison, NJ). The excitation ratio 340/380 was analyzed using 340- and 380-nm wavelengths for excitation and 505 nm for emission. Changes in [Ca\textsuperscript{2+}] were measured and indexed by the alterations in the fluorescence ratio 340/380.

\textbf{Immunohistochemical Staining}—Femur bones from osteoblast-specific BMP-2-null (BMP-2 cKO) and BMP-2 flx/flx (wild type (WT)) mice were fixed for 48 h in 4% phosphate-buffered formalin at 4 °C followed by decalcification in a mixture of 10% EDTA and 4% phosphate-buffered formalin (2.3:1) for 10 days. Decalcified bones were embedded in paraffin, and 8-\mu m sections were prepared, dried, deparaffinized, blocked, and incubated with NFATc1 antibody followed by secondary antibody labeling and detection using an Elite ABC kit (Vector Laboratories Inc., Burlingame, CA) with diaminobenzidine as the chromogen.

\textbf{Statistics}—Analysis of variance with Student-Newman-Keuls analysis followed by Tukey comparison test was used to determine the significance of the data. The means \pm S.E. of the indicated measurements are shown. A \textit{p} value of less than 0.05 was considered significant.

\textbf{Results}—BMP-2 Regulates NFATc1 Expression—BMP-2 is critical in osteoblast differentiation. A role for NFATc1 is also implicated in osteoblast cell proliferation and differentiation (10, 13). To test whether BMP-2 regulates NFATc1, we analyzed NFATc1 protein expression in C2C12 cells, which differentiate into osteoblasts in the presence of BMP-2. BMP-2 dose-dependently increased NFATc1 expression (Fig. 1A). We found 100 ng/ml 70% ethyl alcohol for 1 h at 4 °C, washed with distilled water, and stained for 5 min with a 2% solution of Alizarin Red S, pH 4.0 (Sigma). Plates were dried and photomicrographed.
BMP-2 to be optimum for NFATc1 expression in these cells (Fig. 1, lane 5). Also BMP-2 stimulated NFATc1 protein expression in a time-dependent manner. Increased expression was observed at 6 h and was sustained up to 24 h (Fig. 1, C and D). BMP-2 increased NFATc1 protein expression in 2T3 and FRC cells. Cell lysates from 2T3 (C) or primary FRC osteoblasts (D) treated with BMP-2 for the indicated times were immunoblotted with NFATc1 (upper panel) or actin (lower panel) antibody. E, time kinetics for BMP-2-mediated NFATc1 mRNA expression. RNA was isolated from BMP-2-treated C2C12 cells and analyzed for NFATc1 mRNA expression by qRT-PCR as described under “Experimental Procedures.” The mRNA values were normalized to GAPDH expression in the same sample. Mean ± S.E. of quadruplicate measurements is shown. *, p < 0.05 versus control; **, p < 0.001 versus control; †, p < 0.01 versus control. F–I, BMP-2 regulates NFATc1 and osteogenic gene expression in osteoblasts. RNA was isolated from 2T3 (F and G), osteocalcin (OC) (H), or Runx2 (I) mRNA expression by qRT-PCR using gene-specific primer sets as described above. J and K, BMP-2 specifically activates NFATc1 P1 promoter utilization. RNA isolated from BMP-2-treated C2C12 cells was analyzed by qRT-PCR for utilization of P1 (J) and P2 (K) promoters using specific primer sets as described under “Experimental Procedures.” Mean ± S.E. of quadruplicate measurements is shown. *, p < 0.001 versus control; †, NFAT1 expression is inhibited in osteoblast-specific BMP-2-null mice. Bone sections from BMP-2 flx/flx (WT) and BMP-2 cKO mice were immunohistochemically stained for NFATc1 expression. Error bars represent S.E.

BMP-2 Regulates NFATc1 Expression

FIGURE 1. BMP-2 is necessary for NFATc1 expression in osteoblasts. A, BMP-2 dose-dependently increases NFATc1 expression in C2C12 cells. Cells were incubated with increasing doses of BMP-2 (25, 50, 100, 200, and 300 ng/ml) in serum-free medium followed by immunoblotting with antibodies against NFATc1 (upper panel) and actin (lower panel). B, time kinetics for BMP-2 induced NFATc1 expression. C2C12 cells were treated with 100 ng/ml BMP-2 for 6, 12, 18, and 24 h in serum-free medium followed by immunoblotting with NFATc1 and actin antibodies. C and D, BMP-2 increases NFATc1 protein expression in 2T3 and FRC cells. Cell lysates from 2T3 (C) or primary FRC osteoblasts (D) treated with BMP-2 for the indicated times were immunoblotted with NFATc1 (upper panel) or actin (lower panel) antibody. E, time kinetics for BMP-2 mediated NFATc1 mRNA expression. RNA was isolated from BMP-2 treated C2C12 cells and analyzed for NFATc1 mRNA expression by qRT-PCR as described under “Experimental Procedures.” The mRNA values were normalized to GAPDH expression in the same sample. Mean ± S.E. of quadruplicate measurements is shown. *, p < 0.05 versus control; **, p < 0.001 versus control; †, p < 0.01 versus control. F–I, BMP-2 regulates NFATc1 and osteogenic gene expression in osteoblasts. RNA was isolated from 2T3 (F and G), osteocalcin (OC) (H), or Runx2 (I) mRNA expression by qRT-PCR using gene-specific primer sets as described above. J and K, BMP-2 specifically activates NFATc1 P1 promoter utilization. RNA isolated from BMP-2 treated C2C12 cells was analyzed by qRT-PCR for utilization of P1 (J) and P2 (K) promoters using specific primer sets as described under “Experimental Procedures.” Mean ± S.E. of quadruplicate measurements is shown. *, p < 0.001 versus control; †, NFATc1 expression is inhibited in osteoblast-specific BMP-2-null mice. Bone sections from BMP-2 flx/flx (WT) and BMP-2 cKO mice were immunohistochemically stained for NFATc1 expression. Error bars represent S.E.

In T cells, alternative use of two promoters (P1 and P2) and two poly(A) sites (pA1 and pA2) results in three isoforms (A, B, and C) of NFATc1 transcripts from 11 exons (33). The short isoform A is the most abundant form of NFATc1 in activated T cells and utilizes the distal P1 promoter and proximal pA1 poly(A) site (33). To examine whether there is a preference in promoter utilization by BMP-2 in osteoblasts, we tested expression of NFATc1 mRNA from both these promoters in response to BMP-2. C2C12 cells were incubated with BMP-2, and NFATc1 mRNA expression was quantified using qRT-PCR primers specifically recognizing transcripts from P1 or P2 pro-
BMP-2 Regulates NFATc1 Expression

**FIGURE 2. Smad signaling is involved in BMP-2-induced NFATc1 expression.** A, Smad6 expression in C2C12 cells treated with adenoviral vector expressing Smad 6 (Ad Smad6). Cells were incubated with Ad Smad6 for 24, 48, and 72 h followed by immunoblotting with Smad6 or actin antibody. B, Smad6 blocks BMP-2-induced NFATc1 expression. Cells were preincubated with Ad Smad6 for 48 h followed by BMP-2 treatment. Control cells were preincubated with adenoviral vector expressing GFP (Ad GFP). Cell lysates were immunoblotted with NFATc1, phospho-Smad1/5 (P-Smad 1/5), Smad1/5, or actin antibody. C and D, Smad6 blocks BMP-2-induced NFATc1 mRNA expression (C) and promoter activity (D), RNA isolated from C2C12 cells treated as in B was analyzed for NFATc1 P1-specific mRNA expression as described in Fig. 1J. C2C12 cells were transfected with the 800-bp NFATc1 P1 promoter-driven firefly luciferase construct (NFATc1-Luc) (33) followed by Ad Smad6 or Ad GFP plasmid incubation with or without BMP-2 treatment. Luciferase activities were measured in the cell lysates as described under "Experimental Procedures." In C, mean ± S.E. of quadruplicate measurements is shown. *, p < 0.001 versus control; **, p < 0.001 versus BMP-2-treated. In D, mean ± S.E. of triplicate determinations is shown. *, p < 0.001 versus control; **, p < 0.001 versus BMP-2-treated. E, C2C12 cells were cotransfected with NFATc1-Luc plasmid and Smad5 expression plasmid or empty vector in the presence or absence of BMP-2. Luciferase activities were measured in the cell lysates. Mean ± S.E. of triplicate determinations is shown. **, p < 0.001 versus control; *, p < 0.01 versus control. Error bars represent S.E.

BMP-2 significantly enhanced the NFATc1 mRNA expression from P1 promoter in osteoblast cells (Fig. 1J), whereas mRNA expression from P2 promoter was found to be non-responsive to BMP-2 treatment (Fig. 1K). We used the P1 promoter-driven reporter construct for the remainder of our experiments. To determine whether NFATc1 expression is regulated by BMP-2 in vitro, we used tissue sections from a femur of a BMP-2 cKO mouse (38). These mice show reduction in bone mass, radio-opacity, and bone mineral density. Immunohistochemical staining showed significantly reduced NFATc1 expression in BMP-2 cKO mouse bone compared with the BMP-2/flx/flx (WT) mice (Fig. 1L).

**Smad Signaling Controls NFATc1 Expression—**BMP-2 regulates osteoblastic gene expression by signaling through Smad1/5/8, which is inhibited by Smad6. Therefore, we used an adenovirus vector expressing Smad6 to test the involvement of BMP-specific Smad signaling for NFATc1 expression. Infection of C2C12 cells with the vector (Ad Smad6) showed abundant expression of Smad6 at 48 h (Fig. 2A). C2C12 cells infected with Ad Smad6 for 48 h were incubated with BMP-2. As shown in Fig. 2B, the expression of Smad6 blocked Smad1/5 phosphorylation with a concomitant decrease in BMP-2-induced NFATc1 protein expression (Fig. 2B). Similarly, Smad6 blocked BMP-2-induced NFATc1 mRNA expression in these cells (Fig. 2C). Furthermore, BMP-2-stimulated transcription of NFATc1 from the P1 promoter was significantly inhibited by Smad6 (Fig. 2D). To confirm the involvement of BMP-2-specific Smad in NFATc1 transcription, we tested the effect of Smad5. Expression of Smad5 significantly increased the transcription of NFATc1 to a level similar to levels obtained by BMP-2 treatment (Fig. 2E). Both BMP-2 and expression of Smad5 had an additive effect (Fig. 2E).

**BMP-2 Induces Smad Interaction with NFATc1 Promoter—**Analysis of NFATc1 P1 promoter revealed the presence of three SBEs clustered between −70 and −47 bp (Fig. 3A). We tested interaction of BMP-specific Smads with NFATc1 promoter using a radiolabeled probe spanning the SBEs (−70/−47 bp) in an electrophoretic mobility shift assay (EMSA). BMP-2 increased DNA-protein complex formation (Fig. 3B, compare lane 2 with lane 1). We tested the specificity of DNA-protein interaction using increasing concentrations (1× and 100×) of unlabeled oligonucleotide probe and found reduced formation of DNA-protein complex (Fig. 3B, compare lanes 3 and 4 with lane 2). Unlabeled oligonucleotide specific for the transcription factor AP2 did not compete for protein binding to NFATc1 SBE, confirming the specificity of the DNA-protein interaction (Fig. 3B, lane 5). Interaction of BMP-specific Smads with this SBE region was analyzed by EMSA using Smad-specific antibody. Incubation with antibody specific for Smad1/5 (Fig. 3C, lane 3), but not the non-immune IgG (Fig. 3C, lane 4), prior to the addition of radiolabeled probes in the EMSA reaction specifically blocked BMP-2-induced formation of DNA-protein complex. These results indicate specific binding of BMP-specific Smad1/5 with the SBE in the NFATc1 promoter (Fig. 3C). Next, using a ChIP assay, in vivo association of Smad1/5 with NFATc1 P1 promoter was confirmed (Fig. 3D). Importantly, BMP-2 treatment increased Smad1/5 association with NFATc1 P1 promoter as demonstrated in
the ChIP assay followed by qRT-PCR using primers spanning the SBEs (Fig. 3E).

BMP-2-activated Smad Signaling Is Required for NFATc1 Nuclear Translocation—Our results above show involvement of Smad signaling in BMP-2-induced NFATc1 expression in osteoblast cells. The transcriptional activity of NFATc1 depends on its ability to enter into the nucleus and interact with DNA elements of candidate genes. We analyzed NFATc1 export to the nucleus upon BMP-2 stimulation. BMP-2 significantly increased nuclear localization of NFATc1 (Fig. 3F, compare lane 4 with lane 3). We confirmed the ability of BMP-2 to induce NFATc1 nuclear import using immunofluorescence (Fig. 3G). Expression of Smad6 reduced BMP-2-induced enrichment of NFATc1 in the nuclear compartment of C2C12 cells, indicating involvement of Smad signaling in NFATc1 nuclear translocation (Fig. 3H, compare lane 4 with lane 2). Furthermore, immunofluorescence analysis showed inhibition of BMP-2-stimulated NFATc1 localization by Smad6 (Fig. 3I).

Involvement of PI 3-Kinase Signaling in BMP-2-induced NFATc1 Expression—We reported that BMP-2 utilizes PI 3-kinase/Akt signaling to regulate osteoblast differentiation (25).
To determine the involvement of PI 3-kinase in the BMP-2-mediated increase in NFATc1 protein expression, we used Ly294002 (Ly), a pharmacological inhibitor of PI 3-kinase. Pre-treatment of the cells with Ly significantly inhibited BMP-2-induced NFATc1 protein expression in parallel to the inhibition of Akt phosphorylation, a downstream target of PI 3-kinase, indicating involvement of PI 3-kinase signaling (Fig. 4A). Ly significantly blocked BMP-2-stimulated NFAT mRNA expression (Fig. 4B). PTEN is a specific phosphatase that blocks PI 3-kinase signaling (39). Expression of PTEN blocked phosphorylation of Akt and inhibited expression of NFAT protein and mRNA in response to BMP-2 (Fig. 4C and D). We have shown previously that Akt regulates BMP-2-induced osteoblast differentiation (25). Expression of dominant negative Akt kinase attenuated BMP-2-stimulated NFATc1 protein mRNA expression (Fig. 4, E and F). Similarly, Ly and expression of PTEN or dominant negative Akt significantly decreased the BMP-2-induced transcription of NFATc1 (Fig. 4, G, H, and I). We described above that BMP-2 increased translocation of NFATc1 into the nucleus (Fig. 3, F and G); therefore, we tested the role of PI 3-kinase/Akt signaling in nuclear localization of NFATc1. Both Ly and PTEN inhibited the BMP-2-stimulated NFATc1 import to the nucleus (Fig. 4, J and K). Similarly, expression of dominant negative Akt suppressed the nuclear localization of NFATc1 by BMP-2 (Fig. 4L). Together, our results demonstrate that PI 3-kinase-dependent Akt kinase regulates BMP-2-mediated expression of NFATc1 and its nuclear translocation.
BMP-2 Regulates NFATc1 Expression

BMP-2-stimulated Akt Kinase Inactivates GSK3β and Blocks NFATc1 Nuclear Export—GSK3β has been shown to phosphorylate NFATc1 at selected serine residues, and facilitate its exit from nucleus thereby reducing its transcriptional activity (27). Akt conversely can phosphorylate and inactivate GSK3β (28). In an effort to find out the underlying mechanism of Akt-induced activation of NFATc1, we first tested GSK3β inactivation in response to BMP-2 in osteoblast cells. BMP-2 treatment induced phosphorylation of GSK3β (Fig. 5, A–C). Inactivation of Akt kinase activity by pretreatment with Ly294002 and expression of PTEN and the dominant negative form of Akt blocked BMP-2-induced GSK3β phosphorylation (Fig. 5, A–C). To examine the role of GSK3β in NFATc1 nuclear export in osteoblasts, we examined nuclear localization of NFATc1 in the presence of a pharmacological inhibitor of GSK3β, SB216763. Treatment of osteoblasts with SB216763 increased nuclear localization of NFATc1 under the basal condition (Fig. 5D, compare lanes 1 and 3). However, BMP-2-mediated localization of NFATc1 to the nucleus was not further increased by this treatment (Fig. 5D, compare lanes 2 and 4). These results indicate that Akt-mediated inactivation of GSK3β may increase the nuclear abundance of NFATc1 to enhance its transcriptional activity in osteoblasts.

BMP-2 Induces Interaction of Akt and Smad1/5 to Initiate Cross-talk between These Two Signaling Pathways—We have shown above that BMP-2-induced NFATc1 transcription involves Smad signaling and Akt signaling pathways (Figs. 2–4). To test the possible existence of cross-talk between these two signaling pathways, we first tested whether Smad1/5 and Akt interact with each other in osteoblasts. Lysates of BMP-2-treated cells were immunoprecipitated with Akt antibody followed by immunoblotting with Smad1/5 antibody. The results show that BMP-2 increased the association between Akt and Smad1/5 (Fig. 5E). Reciprocal immunoprecipitation and immunoblotting experiments showed similar results (Fig. 5F). These results indicate a possible cross-talk between Akt and Smad1/5. To determine the involvement of this cross-talk, we examined the transcriptional activation of NFATc1 using the reporter construct. NFATc1 promoter was transfected with Smad5 and/or PTEN expression vector. The transfected cells were incubated with BMP-2. As shown in Fig. 5G, both BMP-2 and Smad5 increased the transcription of NFATc1. Expression of PTEN, which inhibits the Akt kinase activity, significantly blocked BMP-2-as well as Smad 5-induced transcription of NFATc1 (Fig. 5G). Similarly, expression of dominant negative Akt inhibited NFATc1 transcription in response to BMP-1 and Smad5 (Fig. 5H). These results indicate the requirement of concerted action of Akt and Smad signaling in BMP-2-induced NFATc1 promoter activation.

BMP-2 Mobilizes Intracellular Ca2+ to Induce Calcineurin Activity and Osteoblast Differentiation—NFATc1 activation and nuclear localization require Ca2+-mediated activation of calcineurin phosphatase. We first examined the effect of BMP-2 on Ca2+ mobilization. Incubation of C2C12 cells with BMP-2 transiently increased the release of intracellular Ca2+ (Fig. 6A) that was abrogated upon pretreatment of the cells with...
the selective endoplasmic reticulum Ca\(^{2+}\) pump inhibitor thapsigargin, which promotes depletion of intracellular Ca\(^{2+}\) (Fig. 6B). NFATc1 activation requires Ca\(^{2+}\)-dependent calcineurin phosphatase activity. Therefore, we analyzed the effect of BMP-2 on calcineurin phosphatase activity in C2C12 cells using an in vitro phosphatase assay (40). Treatment with BMP-2 resulted in a 2-fold increase in calcineurin activity (Fig. 6C).

BMP-2 induces differentiation of C2C12 cells into mature osteoblasts. Our results above demonstrate a role of BMP-2 in Ca\(^{2+}\) release from the intracellular store and activation of calcineurin. Therefore, we first examined the role of Ca\(^{2+}\) in osteoblast differentiation using the intracellular Ca\(^{2+}\) chelator BAPTA-AM. Expression of alkaline phosphatase acts as a marker for osteoblast differentiation. BMP-2 increased alkaline phosphatase activity in C2C12 cells (Fig. 6D). Treatment of these cells with BAPTA-AM prior to incubation with BMP-2 significantly inhibited the BMP-2-stimulated alkaline phosphatase activity (Fig. 6D). Consequently, BAPTA-AM abrogated BMP-2-induced differentiation of C2C12 cells into mature osteoblasts as judged by Alizarin Red assay (Fig. 6E). Similarly, cyclosporin A (CsA), a pharmacological inhibitor of calcineurin, blocked BMP-2-mediated alkaline phosphatase activity and osteoblast differentiation (Fig. 6F and 6G). These results indicate a requirement for Ca\(^{2+}\)-calcinurin, which may regulate BMP-2-induced NFATc1 expression for osteoblast differentiation.

**Ca\(^{2+}/\)**Calcineurin Signaling Contributes to BMP-2-stimulated NFATc1 Expression and Autoregulation—To determine the involvement of calcineurin phosphatase activity in BMP-2-induced NFATc1 expression, we used CsA. CsA abolished the BMP-2-mediated increase in expression of NFATc1 protein
and mRNA (Fig. 7, A and B). Similarly, BMP-2-induced transcription of NFATc1 was also inhibited by CsA (Fig. 7C). The intracellular Ca\(^{2+}\) chelator BAPTA-AM blocked BMP-2-induced NFATc1 protein and mRNA expression and its transcriptional activation (Fig. 7, D, E, and F), indicating an inherent role of Ca\(^{2+}\) in BMP-2-induced NFATc1 expression. To directly investigate the involvement of NFATc1 in its transcription, we cotransfected the cells with NFATc1 promoter-luciferase reporter plasmid (NFATc1-Luc) and the NFATc1 expression vector. Incubation of these cells with BMP-2 increased the transcription of NFATc1. However, expression of NFATc1 significantly increased the transcription similarly to that obtained with BMP-2 (Fig. 7G). Both BMP-2 and NFATc1 had an additive effect on NFATc1 transcription (Fig. 7G). Conversely, expression of VIVIT peptide, a specific inhibitor of NFATc1, blocked BMP-2-induced transcription of NFATc1 (Fig. 7H). NFATc1 was shown to bind to NFATc1 P1 promoter and autoregulate its own transcription (33). To test the association of
BMP-2 Regulates NFATc1 Expression

NFATc1 with NFATc1 P1 promoter in osteoblasts, we used an oligonucleotide for NFAT binding element spanning −700 to −661 bp as described by Chuvpilo et al. (33) in an electrophoretic mobility shift assay. DNA-protein interaction was observed using nuclear extract isolated from osteoblast cells (Fig. 7I, lane 1), and this was increased by BMP-2 treatment (Fig. 7I, compare lane 2 with lane 1). The specificity of this DNA-protein interaction was confirmed by incubating with cold oligonucleotide that was used as radioactive probe in this assay. Incubation of the nuclear extract with 100-fold excess cold NFATc1 oligonucleotide probe followed by radioactively labeled probe in this assay abolished association of radioactive probe with the nuclear protein (Fig. 7I, compare lane 4 with lane 2). Incubation with a 100-fold excess of a nonspecific oligonucleotide did not alter the specific association of radiolabeled NFATc1 probe with osteoblastic nuclear proteins (Fig. 7I, compare lane 5 with lane 2). Interaction of NFATc1 with NFAT P1 promoter in osteoblasts was confirmed using a ChIP assay. The ChIP assay with NFATc1 antibody and subsequent PCR using primers specific for the NFATc1 binding sites in P1 promoter confirmed binding of NFATc1 with P1 promoter (Fig. 7J). BMP-2 treatment augmented this interaction of NFATc1 on P1 promoter (Fig. 7K). These results suggest a role of Ca²⁺-dependent calcineurin in BMP-2-mediated expression of NFATc1, which in turn feeds forward to autoregulate its expression.

Discussion

Bone remodeling is controlled by cooperative actions of osteoblasts and osteoclasts. The calcium-sensitive NFATc1 transcription factor regulates osteoclast differentiation downstream of the osteoblast-coded factors RANKL and CSF-1, expression of which is in turn controlled by BMP-2 (12, 18, 19, 41). Our study shows the presence of an autoregulatory loop for NFATc1 expression in BMP-2-stimulated osteoblasts that drives their differentiation. Moreover, our study identified a novel role of BMP-2 in stimulating intracellular Ca²⁺ release and calcineurin phosphatase activity necessary for NFATc1 gene expression in osteoblasts. Additionally, BMP-2 integrates its receptor-specific Smad pathway and PI 3-kinase/Akt signaling to induce expression of NFATc1 and its nuclear translocation in osteoblast cells (Fig. 8).

Mice overexpressing the constitutively activated form of NFATc1 in osteoblasts developed a high bone mass phenotype resulting from increased osteoblast function (13). As a possible mechanism, it was demonstrated that NFATc1 functions in recruiting osteoclast progenitors by increasing chemoattractant production by osteoblasts (13). Studies from mice treated with the calcineurin inhibitor FK506 showed a decrease in osteoclast number and activity leading to decreased bone resorption. Surprisingly, FK506 treatment also decreased trabecular bone volume, indicating a role of NFATc1 in osteoblastic bone formation (41). A similar bone phenotype of low bone mass was observed in BMP-2 cKO mice (38). Immunohistochemical staining of trabecular bone sections from these BMP-2 cKO mice showed significant reduction in NFATc1 expression (Fig. 1L). Indeed, BMP-2 was found to induce NFATc1 mRNA and protein expression in osteoblast cells in a dose- and time-dependent manner (Fig. 1, A–G).

Regulation of NFATc1 expression has been extensively studied in T lymphocytes in response to antigen exposure. In these cells, NFATc1 is synthesized in three isoforms due to differential use of the polyadenylation sites (42). As an additional control mechanism, two distinct promoters, namely P1 and P2, regulate NFATc1 expression in T lymphocytes (33). The P1 promoter contains binding sites for a number of transcription factors and resides within a CpG island proximal to exon 1 of NFATc1 gene. P1 promoter is hypermethylated in kidney cells where NFATc1 is not expressed and is demethylated in effector T cells with increased NFATc1 expression (33). The studies conducted by the same group identified a binding region for a number of transcription factors including NFκB, Sp1, Sp3, and NFAT within the 800-bp P1 promoter. Coordinated interaction of these factors with P1 promoter regulates NFATc1 expression in the effector T cells. We show that BMP-2 preferentially stimulated NFATc1 mRNA expression from P1 promoter, whereas the P2 promoter remained unresponsive to BMP-2 in the preosteoblast cells (Fig. 1, J and K). Autoregulation of NFATc1, driven by the two NFATc1 binding regions in P1 promoter, was identified in effector T lymphocytes (33). We explored the possibility of NFATc1 promoter autoregulation in osteoblast cells and demonstrated robust stimulation of the P1 promoter activity by NFATc1 that is further augmented by treatment with BMP-2, acting by facilitating NFATc1 nuclear import (Fig. 3, F and G). We show that BMP-2-mediated NFATc1 autoregulatory function in osteoblasts was due to direct association of NFATc1 with NFATc1 P1 promoter at the NFATc1 binding site (Fig. 7, I, J, and K) (33). This observation for the first time demonstrates that BMP-2 selectively targets P1 promoter to induce NFATc1 expression, which in turn feeds forward to further potentiate its own expression in osteoblasts.

BMP-2 orchestrates signaling through Smad proteins for regulating expression of osteoblastic genes necessary for the
osteoblast differentiation program (30). BMP-2-induced NFATc1 expression and nuclear localization were blocked by exogenous expression of the inhibitory Smad6 that targets BMP-specific Smad signaling (Figs. 2 and 3), indicating a direct role of Smads in osteoblastic expression and activation of NFATc1. We have established a requirement for PI 3-kinase and its downstream target Akt kinase in BMP-2-mediated osteoblast differentiation (25). Using expression plasmids for PTEN and dominant negative Akt kinase along with a pharmacological inhibitor for PI 3-kinase/Akt signaling pathway for NFATc1 protein and mRNA expression in BMP-2-stimulated preosteoblast cells (Fig. 4).

Different signaling pathways communicate and cooperate to maintain the fine balance in gene expression. Such a signaling cross-talk exists between PI 3-kinase/Akt and Smad signaling in BMP-2-mediated CSF-1 gene expression in osteoblast cells (15). We show that BMP-2-mediated NFATc1 expression also required cooperative inputs from Smad and PI 3-kinase/Akt signaling (Fig. 5, G and H). Toward this signaling cross-talk, we show that BMP-2 induced association of Akt and Smad1/5 in osteoblasts (Fig. 5, E and F). In T cells, activation and nuclear import of NFATc1 require dephosphorylation by calcineurin, whereas GSK3β phosphates and expels NFATc1 from the nucleus (9, 27). Activity of GSK3β is inhibited by phosphorylation at the Ser-9 residue (43). Akt kinase directly phosphorylates and inactivates GSK3β in response to insulin (28). We previously showed that BMP-2 activates Akt kinase in osteoblasts (25). Here we show that BMP-2 increased phosphorylation of GSK3β in Akt-dependent manner (Fig. 5, A–C). Phosphorylation of GSK3β also increased nuclear accumulation of NFATc1 (Fig. 5D), thus facilitating NFATc1 autoregulation and transcriptional activation. Taken together, we identified a mechanism through which BMP-2-induced Akt activation results in increased expression of NFATc1 in osteoblasts.

Calcium signaling plays a key role in osteoblast proliferation and differentiation. Parathyroid hormone and vitamin D3 increase intracellular Ca2+ concentrations in osteoblasts by mobilizing Ca2+ stored in intracellular organelles (44, 45). Both TGFβ and BMP-2 enhance adhesion of human osteoblast cells to biomaterials and thus improve the functionality of orthopedic implants (46). Intracellular Ca2+ signaling plays an essential role in TGFβ-induced increased adhesion of human osteoblast cells (47). In pulmonary arterial smooth muscle cells, although BMP-4 induces an intracellular Ca2+ increase, BMP-2 was found to inhibit it (48, 49). This observation explained the opposing functions of BMP-4 and BMP-2 toward chronic hypoxic pulmonary hypertension where BMP-2 plays the preventative role and BMP-4 promotes vascular remodeling. We found BMP-2 to induce a rapid and transient rise in intracellular Ca2+ that was blocked when the cells were treated with the endoplasmic reticulum-specific Ca2+ pump inhibitor thapsigargin (Fig. 6, A and B). The importance of Ca2+ signaling in BMP-2-induced osteoblastic gene expression and osteoblast differentiation is unknown. Based on the fact that NFATc1 activation depends on Ca2+-directed calcineurin phosphatase activity, we measured calcineurin phosphatase activity in osteoblast cells treated with BMP-2. We found induction of calcineurin phosphatase activity in preosteoblasts in response to BMP-2 (Fig. 6C). Blocking of intracellular Ca2+ release by BAPTA-AM or inhibiting calcineurin activity by CsA dampened BMP-2-induced alkaline phosphatase activity and mineralized nodule formation in these cells (Fig. 6, D–G). This confirms a direct involvement of Ca2+-driven calcineurin activity in BMP-2-mediated osteoblast differentiation. In addition, BAPTA-AM and CsA inhibited BMP-2-induced NFATc1 protein and mRNA expression (Fig. 7, A–F), indicating a requirement of Ca2+ signaling and calcineurin phosphatase activity for BMP-2-mediated NFATc1 expression in these cells.

In summary, we report here a novel mechanism of osteoblastic NFATc1 expression and autoregulation in response to BMP-2 that involves orchestration of signaling pathways involving Ca2+, Smads, and PI 3-kinase/Akt (Fig. 8). Also we provide evidence for the involvement of Ca2+/calcineurin signaling in osteoblast differentiation downstream of BMP-2. Whether BMP-2-mediated Ca2+ signaling plays a role in the Smad and PI 3-kinase signaling pathway in relation to bone remodeling will be of interest and will need further investigation.

Author Contributions—The experiments were mainly performed by C. C. M. with substantial contribution from F. D. S. G. performed immunohistochemical analysis. S. E. H. provided the BMP-2 CKO mice for this study. G. G. C. provided critical input in designing experiments, data analyses, and manuscript preparation. N. G.-C. formulated the study, analyzed data, and prepared the manuscript.

References

1. Capulli, M., Paone, R., anducci, N. (2014) Osteoblast and osteocyte: games without frontiers. Arch. Biochem. Biophys. 561, 3–12
2. Negishi-Koga, T., and Takayanagi, H. (2009) Ca2+/NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev. 231, 241–256
3. Eapen, A., Sundivakkam, P., Song, Y., Ravindran, S., Ramachandran, A., Tiruppathi, C., and George, A. (2010) Calcium-mediated stress kinase activation by DMP1 promotes osteoblast differentiation. J. Biol. Chem. 285, 36339–36351
4. Blair, H. C., Robinson, L. J., Huang, C. L., Sun, L., Friedman, P. A., Schlesinger, P. H., and Zaidi, M. (2011) Calcium and bone disease. Biofactors 37, 159–167
5. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T. (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600–2602
6. Takami, M., Takahashi, N., Udagawa, N., Miyaura, C., Suda, K., Woo, J. T., Martin, T. J., Nagai, K., and Suda, T. (2000) Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kB ligand and osteoprotegerin in osteoblasts. Endocrinology 141, 4711–4719
7. Lee, H. L., Bae, O. Y., Baek, K. H., Kwon, A., Hwang, H. R., Qadir, A. S., Park, H. J., Woo, K. M., Ryoo, H. M., and Baek, J. H. (2011) High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of nuclear factor-kB ligand in osteoblasts. Bone 49, 242–249
8. Shaw, J. P., Utz, P. J., Durand, D. B., Tooie, J. L., Emmel, E. A., and Crabtree, G. R. (1988) Identification of a putative regulator of early T cell activation genes. Science 241, 202–205
9. Beals, C. R., Clipstone, N. A., Ho, S. N., and Crabtree, G. R. (1997) Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev. 11, 824–834
10. Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima, K., and Takayanagi, H. (2005) NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11, 880–885
and Tuan, R. S. (2007) TGF-β1 calcium signaling in osteoblasts. J. Cell. Biochem. 101, 348–359
48. Zhang, Y., Lu, W., Yang, K., Xu, L., Lai, N., Tian, L., Jiang, Q., Duan, X., Chen, M., and Wang, J. (2013) Bone morphogenetic protein 2 decreases TRPC expression, store-operated Ca\^{2+} entry, and basal [Ca\^{2+}], in rat distal pulmonary arterial smooth muscle cells. Am. J. Physiol. Cell Physiol.

304, C833–C843
49. Lu, W., Ran, P., Zhang, D., Lai, N., Zhong, N., and Wang, J. (2010) Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca\^{2+} entry, and basal [Ca\^{2+}], in rat distal pulmonary arterial smooth muscle cells. Am. J. Physiol. Cell Physiol. 299, C1370–C1378